|
시장보고서
상품코드
2052792
혈우병 치료 시장 : 제품 유형별, 유통 채널별, 지역별Hemophilia Treatment Market, By Product Type, By Distribution Channel, By Geography |
||||||
혈우병 치료 시장은 2026년에 183억 490만 달러로 추정되며, 2033년까지 285억 180만 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 6.5%로 성장할 것으로 전망됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도: | 2025년 | 2026년 시장 규모: | 183억 490만 달러 |
| 과거 데이터 기간: | 2020-2024년 | 예측 기간: | 2026-2033년 |
| 2026년부터 2033년까지 예측 기간 CAGR: | 6.50% | 2033년 시장 규모 예측: | 285억 180만 달러 |
혈우병은 제8인자 등 응고인자라고 불리는 단백질이 부족하거나 그 수치가 낮은 유전성 출혈성 질환입니다. 혈액 응고를 돕기 위해 혈소판과 협력하여 작용하는 응고인자는 약 13가지가 있습니다. 혈우병에는 A형, B형, C형 세 가지 유형이 있습니다. 혈우병 A형은 가장 흔한 유형으로 제8인자 결핍에 의해 발생합니다. 혈우병 B형은 인자 IX의 결핍으로 인해 발생하며, 혈우병 C형은 인자 XI의 결핍으로 인해 발생합니다. 대부분의 경우 혈우병은 유전으로 인해 가족 내에서 유전됩니다. 주로 남자아이들에게 물려받습니다. 혈우병의 주요 치료법은 정맥 주사를 통해 혈액 내 응고인자를 보충하는 것입니다. 그러나 혈우병 치료의 높은 비용, 의약품 부족, 혈장 유래 제품과 관련된 심각한 부작용이 시장 성장을 저해할 것으로 예상됩니다. 그 결과, 예측 기간 동안 혈우병성 질환의 유병률과 유병률의 증가는 시장 성장을 촉진할 것으로 예상됩니다. 이에 따라 주요 기업들은 소비자의 미충족 수요를 충족시키기 위해 신제품을 출시하고 있습니다. 제품 출시 및 치료와 관련된 우호적인 규제 환경과 가이드라인도 예측 기간 동안 시장 성장을 촉진할 것으로 예상되는 요인입니다.
시장 역학
혈우병 치료를 위한 정부의 노력이 증가함에 따라 예측 기간 동안 혈우병 치료 시장의 성장을 촉진할 것으로 예상됩니다. 예를 들어, 2022년 6월 미국 국립의학도서관(National Library of Medicine)에 게재된 기사에 따르면, 세계혈우연맹(WFH)은 인도주의 지원 프로그램을 통해 저소득 및 중저소득 국가에 응고인자 농축제제 및 에미시주맙을 배포하기 시작했습니다. 배포를 시작했습니다. 이 프로그램은 개발도상국의 제한된 수의 혈우병 환자(PWH)들의 삶을 개선하는 데 기여할 것입니다.
본 조사의 주요 특징
- 이 보고서는 각 부문의 잠재적 수익기회를 파악하고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략에 대한 중요한 인사이트를 제공합니다.
- 이 보고서는 세계 혈우병 치료 시장의 주요 기업 프로파일을 회사 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 성과 및 전략과 같은 매개 변수를 기반으로 작성되었습니다.
- 이 보고서의 내용을 통해 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있을 것입니다.
- 세계 혈우병 치료 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 혈우병 치료 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 가정
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 혈우병 치료 시장 : 제품 유형별, 2021-2033년
제5장 세계의 혈우병 치료 시장 : 유통 채널별, 2021-2033년
제6장 세계의 혈우병 치료 시장 : 지역별, 2021-2033년
제7장 경쟁 구도
제8장 섹션
KSM 26.06.17Hemophilia Treatment Market is estimated to be valued at USD 18,304.9 Mn in 2026 and is expected to reach USD 28,501.8 Mn by 2033, growing at a compound annual growth rate (CAGR) of 6.5% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 18,304.9 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 6.50% | 2033 Value Projection: | USD 28,501.8 Mn |
Hemophilia is a genetic bleeding disorder in which an individual lacks or has low levels of proteins named clotting factor such as factor VIII. There are around 13 types of clotting factors that work with blood platelets to help in clotting of blood. There are three forms of hemophilia - A, B, and C. Hemophilia A is the most common form and is caused due to deficiency of factor VIII. Hemophilia B occurs due to deficiency of factor IX, and Hemophilia C is caused due to factor XI deficiency.In most cases, hemophilia is passed down through families that are inherited. It is mostly passed to the male childrens. The primary treatment for hemophilia is to replace the clotting factor in the blood though intravenous infusions. However, high cost of hemophilia treatment, lack of medicines and serious adverse events associated with plasma derived derived products is expected to hinder the market growth. Consequently, rising incidence and prevalence of hemophilic disorders are expected to boost growth of the market over the forecast period. This has led to product launches by key players to fulfill the unmet needs of consumers. Favorable regulatory scenarios and guidelines for the product launches and treatment are other factors that are expected to propel growth of the market over the forecast period.
Market Dynamics
Increasing government initiatives towards hemophilia treatment is likely expected to propel the growth of hemophilia treatment market over the forecast period. For instance, according to the article published in National Library of Medicine in June 2022, World Federation of Hemophilia(WFH) started distribution of coagulation factor concentrates and emicizumab in low- and low-middle-income countries through a humanitarian aid program. This programwill hwlp to improve life of a limited number of PWH in the developing world.
Key features of the study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global hemophilia treatment market based on the following parameters-Company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Takeda Pharmaceutical Co., Ltd., Sanofi S.A., Octapharma AG, Swedish Orphan Biovitrum AB, Baxter International Inc., Biogen Inc., Bayer AG, CSL Behring, Ferring B.V., Pfizer, Inc., Kedrion, Novo Nordisk A/S, and F. Hoffmann-La Roche AG.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- Global hemophilia treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hemophilia treatment market.
Market Segmentation
- Global Hemophilia Treatment Market, By Product Type (Revenue, USD Mn, 2021 - 2033)
- Plasma Derived Coagulation Factor
- Recombinant Coagulation Factor
- Antifibrinolytic Agents
- Desmopressin
- Global Hemophilia Treatment Market, By Distribution Channel (Revenue, USD Mn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Hemophilia Treatment Market, By Region (Revenue, USD Mn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Company Profiles
- Takeda Pharmaceutical Co., Ltd.
- Sanofi S.A.
- Octapharma AG
- Swedish Orphan Biovitrum AB
- Baxter International Inc.
- Biogen Inc
- Bayer AG
- CSL Behring
- Ferring B.V.
- Pfizer, Inc.
- Kedrion
- Novo Nordisk A/S
- F. Hoffmann-La Roche AG
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Product Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Product Launches
- Epidemiology
- Merger, Acquisition, and Collaborations
- Regulatory Scenario
- Key Developments
- PEST Analysis
4. Global Hemophilia Treatment Market, By Product Type, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Recombinant Coagulation Factor
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Plasma Derived Coagulation Factor
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Antifibrinolytic Agents
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Desmopressin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
5. Global Hemophilia Treatment Market, By Distribution Channel, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
6. Global Hemophilia Treatment Market, By Region, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2021 - 2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (USD Mn)
- North Africa
- Central Africa
- South Africa
7. Competitive Landscape
- Takeda Pharmaceutical Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Sanofi S.A.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Octapharma AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Swedish Orphan Biovitrum AB
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Baxter International Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Biogen Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Bayer AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- CSL Behring
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Ferring B.V.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Pfizer, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Kedrion
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Novo Nordisk A/S
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- F. Hoffmann-La Roche AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
8. Section
- Research Methodology
- About Us
